Pathway Medical's Jetstream G2 NXT catheter boosts its growth by 172 percent over the last two quarters

NewsGuard 100/100 Score

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States. This significant company milestone comes on the heels of Pathway’s recent launch of the Jetstream G2™ NXT, a 7 French compatible version of its peripheral revascularization catheter. Pathway’s transformational technology will be on display at TCT 2009, taking place September 21-25, 2009 at the Moscone Center in San Francisco.

“The number of patients in the U.S. afflicted with PVD is expected to grow exponentially over the next 10 years,” said Pathway Medical Technologies President and CEO Paul Buckman. “Our newest products, including Jetstream G2 NXT with 7 French compatibility, demonstrate our continued commitment to delivering best-in-class revascularization solutions for the PVD market. The fact that physicians and patients alike are embracing Jetstream as an effective, first-line treatment option to remove all types of hard and soft tissue plaque underscores its clinical utility and versatility. We are excited about the momentum achieved in the past 12 months and look forward to securing our place as the leader in PVD innovations in the months to come.”

Jetstream G2 NXT is based on Pathway’s state-of-the-art catheter technology capable of treating the entire spectrum of disease found in patients suffering from PVD, including calcium, soft plaque, fibrotic lesions and thrombus. 7 French compatibility allows physicians to use Jetstream G2 NXT in the treatment of PVD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology.

Pathway Medical Technologies, Inc. will exhibit at TCT 2009 in booth #800. Media interested in meeting with Pathway at the conference should contact Marisa Borgasano or Rebecca Phillips at Schwartz Communications, (415) 512-0770 or [email protected].

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experts recommend shortening the blanking period after atrial fibrillation ablation